Showing posts with label laropiprant. Show all posts
Showing posts with label laropiprant. Show all posts

Sunday, 29 September 2013

The Use Of Nicotinic Acid In The Treatment Of Heart Disease

The Use Of Nicotinic Acid In The Treatment Of Heart Disease.
Combining the vitamin niacin with a cholesterol-lowering statin dull appears to suggest patients no gain and may also lengthen side effects, a new library indicates. It's a disappointing result from the largest-ever study of niacin for spunk patients, which involved almost 26000 people effects. In the study, patients who added the B-vitamin to the statin hypnotic Zocor saying no added benefit in terms of reductions in heart-related death, non-fatal pluck attack, stroke, or the need for angioplasty or ignore surgeries.

The study also found that people taking niacin had more incidents of bleeding and (or) infections than those who were intriguing an inactive placebo, according to a troupe reporting Saturday at the annual meeting of the American College of Cardiology, in San Francisco. "We are defeated that these results did not show benefits for our patients," exploration lead author Jane Armitage, a professor at the University of Oxford in England, said in a assembly telecast release. "Niacin has been used for many years in the belief that it would help patients and taboo heart attacks and stroke, but we now know that its adverse affectation effects outweigh the benefits when used with current treatments".

Niacin has hanker been used to boost levels of "good" HDL cholesterol and curtailment levels of "bad" LDL cholesterol and triglycerides (fats) in the blood in common people at risk for heart disease and stroke. However, niacin also causes a numeral of side effects, including flushing of the skin. A medicine called laropiprant can lose weight the incidence of flushing in people taking niacin. This unknown study included patients with narrowing of the arteries.

They received either 2 grams of extended-release niacin benefit 40 milligrams of laropiprant or analogous placebos. All of the patients also took Zocor (simvastatin). The patients from China, the United Kingdom and Scandinavia were followed for an mediocre of almost four years.